The European Commission (EC) has approved a new Opdivo (nivolumab) formulation associated with a new route of administration ...

Princeton: Bristol Myers Squibb has received approval from the European Commission (EC) for a new Opdivo (nivolumab) ...

Bristol Myers Squibb receives European approval for subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Thursday, May 29, 2025, 15:0 ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

Dr Marjorie Green, head of global clinical development, oncology, at Merck Research Labs, said the subcutaneous route "has the potential to improve the patient experience as well as increase ...

Bristol Myers Squibb today announced that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025. The company will take part in a ...

Garmin today announced SmartCharts, a dynamic aviation charting solution that will provide pilots with a simplified and ...

Many of the biologic drugs that have made the switch from infusion to subcutaneous route have done so with the help of the Enhanze technology developed by Lindy rival Halozyme, which has also been ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

The Global On Body Drug Delivery Devices Market is projected to grow from $40.54B in 2024 to $82.74B by 2033, expanding at a CAGR of 8.6% during 2025-2033. Driven by rising chronic diseases and demand ...

Provision of therapy via the subcutaneous (SC) route is common in palliative care practice for the continuous administration of medication for symptom relief. However, with the exception of opioids ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...